AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11805744 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation interventions for women with CVD
Number of subjects: 277
Study 10593367 — intervention group
Group type: EXPERIMENTAL
Intervention: Crinone 8% (90 mg) once daily
Number of subjects: 86
Study 10593367 — intervention group
Group type: COMPARATOR
Intervention: IM progesterone (100 mg) once daily
Number of subjects: 86
Study 9061429 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic prostatitis
Number of subjects: 99
Study 9061429 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoma
Number of subjects: 99
Study 9061429 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatic neoplasm
Number of subjects: 99
Study 9061429 — intervention group
Group type: COMPARATOR
Intervention: Normal levels (control)
Number of subjects: 99
Study 1711274 — intervention group
Group type: COMPARATOR
Intervention: H1- + H2- antagonists
Number of subjects: 0
Study 1711274 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 0
Study 6363098 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 1 mg from a pressurised aerosol
Number of subjects: 13
Study 6363098 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 1 mg from a nebuliser
Number of subjects: 13
Study 6363098 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 1 mg from a pressurised aerosol with a pear‐shaped, 750 ml spacer
Number of subjects: 13
Study 6363098 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 1 mg from a nebuliser with Intermittent Positive Pressure Ventilation (I.P.P.V.)
Number of subjects: 13
Study 6363098 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 4 mg from a nebuliser
Number of subjects: 13
Study 31533635 — intervention group
Group type: EXPERIMENTAL
Intervention: Health facilities (HFs) readiness index
Number of subjects: 18
Study 31533635 — intervention group
Group type: EXPERIMENTAL
Intervention: Health facilities readiness by district
Number of subjects: 18
Study 31533635 — intervention group
Group type: EXPERIMENTAL
Intervention: Health facilities readiness by level
Number of subjects: 18
Study 31533635 — intervention group
Group type: COMPARATOR
Intervention: Comparison of readiness between health facility levels
Number of subjects: 18
Study 31533635 — intervention group
Group type: COMPARATOR
Intervention: Difference in readiness between HCIIIs and HCIVs
Number of subjects: 18
Study 29510423 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) exposure
Number of subjects: 406
Study 29510423 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal neurodevelopment)
Number of subjects: 406
Study 26472295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling vest
Number of subjects: 10
Study 26472295 — intervention group
Group type: COMPARATOR
Intervention: No vest (Control)
Number of subjects: 10
Study 25279465 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 0
Study 25279465 — intervention group
Group type: COMPARATOR
Intervention: Idarubicin
Number of subjects: 0
Study 25279465 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched donor allogeneic transplant
Number of subjects: 0
Study 22958623 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol succinate (increasing doses to achieve target resting HR <70 beats per minute)
Number of subjects: 20
Study 22958623 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol succinate (increasing doses)
Number of subjects: 20
Study 20884731 — intervention group
Group type: EXPERIMENTAL
Intervention: Project MYTRI intervention program
Number of subjects: 32
Study 20884731 — intervention group
Group type: EXPERIMENTAL
Intervention: Training teachers
Number of subjects: 32
Study 20884731 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher proportion of students participating in classroom discussions
Number of subjects: 32
Study 20884731 — intervention group
Group type: EXPERIMENTAL
Intervention: Better peer-leader-student communication
Number of subjects: 32
Study 20884731 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led health activism
Number of subjects: 32
Study 18979450 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cardiovascular autonomic neuropathy (CAN)
Number of subjects: 39
Study 18979450 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without cardiovascular autonomic neuropathy (CAN)
Number of subjects: 39
Study 18979450 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 sex and age-matched healthy adults)
Number of subjects: 39
Study 16702899 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) administered Hamilton Depression Rating Scale (HAM-D) scores before randomization
Number of subjects: 26168
Study 16702899 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) administered Hamilton Depression Rating Scale (HAM-D) scores after randomization
Number of subjects: 26168
Study 16702899 — intervention group
Group type: EXPERIMENTAL
Intervention: First-time IVR HAM-D scores before randomization
Number of subjects: 26168
Study 12806565 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-g piracetam infusion
Number of subjects: 64
Study 12806565 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile saline)
Number of subjects: 64
Study 11061765 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan NS 10 mg
Number of subjects: 653
Study 11061765 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan NS 20 mg
Number of subjects: 653
Study 11061765 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan NS 5 mg
Number of subjects: 653
Study 9358957 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 50
Study 9358957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 1543140 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release diltiazem (180 mg twice daily)
Number of subjects: 60
Study 1543140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2866727 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane and oxygen
Number of subjects: 115
Study 2866727 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide and oxygen
Number of subjects: 115
Study 2866727 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication a) (pethidine, promethazine, and atropine)
Number of subjects: 115
Study 2866727 — intervention group
Group type: COMPARATOR
Intervention: Other premedications
Number of subjects: 115
Study 2866727 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 115
Study 2866727 — intervention group
Group type: EXPERIMENTAL
Intervention: Premedication a)
Number of subjects: 115
Study 31878966 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy in Daily Life (ACT-DL) in addition to treatment as usual (TAU)
Number of subjects: 0
Study 31878966 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 0
Study 29866368 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance training
Number of subjects: 62
Study 29866368 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 62
Study 29866368 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined moderate-intensity training
Number of subjects: 62
Study 29866368 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-mediated dilation
Number of subjects: 62
Study 29866368 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelium-dependent and endothelium-independent function of the skin microcirculation
Number of subjects: 62
Study 26876349 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement (n = 20)
Number of subjects: 40
Study 26876349 — intervention group
Group type: COMPARATOR
Intervention: Delayed implant placement (n = 20)
Number of subjects: 40
Study 25425730 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (1000 mg/once daily) plus prednisolone (5 mg/twice daily)
Number of subjects: 46
Study 22377805 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (valgus knee brace, customised neutral foot orthoses, shoes designed for motion control)
Number of subjects: 80
Study 22377805 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (neutral knee brace, flat unsupportive foot orthoses, shoes with flexible mid‐sole)
Number of subjects: 80
Study 20855384 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intervention to foster child development
Number of subjects: 128
Study 20855384 — intervention group
Group type: COMPARATOR
Intervention: Surveillance (control)
Number of subjects: 128
Study 18286231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine (CIN)
Number of subjects: 125
Study 18286231 — intervention group
Group type: COMPARATOR
Intervention: Sodium Valproate (SV)
Number of subjects: 125
Study 16318658 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.3 mL of 0.5% levobupivacaine with fentanyl 15 microg
Number of subjects: 50
Study 16318658 — intervention group
Group type: COMPARATOR
Intervention: 2.6 mL of 0.5% levobupivacaine alone
Number of subjects: 50
Study 14502033 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10797115 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion (CHO) - 250 ml of an 8% carbohydrate‐electrolyte solution every 15 min
Number of subjects: 11
Study 10797115 — intervention group
Group type: COMPARATOR
Intervention: Sweet placebo (Control)
Number of subjects: 11
Study 8880041 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet with fish oil supplementation
Number of subjects: 32
Study 8880041 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet without fish oil supplementation
Number of subjects: 32
Study 8880041 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-fat diet with fish oil supplementation
Number of subjects: 32
Study 8880041 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-fat diet without fish oil supplementation
Number of subjects: 32
Study 7955295 — intervention group
Group type: EXPERIMENTAL
Intervention: CSI lens
Number of subjects: 63
Study 7955295 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus lens
Number of subjects: 63
Study 7955295 — intervention group
Group type: COMPARATOR
Intervention: Surevue lens
Number of subjects: 63
Study 7955295 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic patients
Number of subjects: 63
Study 3496470 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightly 160 mg trimethoprim and 800 mg sulfamethoxazole
Number of subjects: 46
Study 3496470 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day antibiotic treatment
Number of subjects: 46
Study 3496470 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day antibiotic therapy
Number of subjects: 46
Study 3496470 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppressive antibiotics, treatment of asymptomatic urinary tract infections, full course antibiotic therapy
Number of subjects: 46
Study 3496470 — intervention group
Group type: COMPARATOR
Intervention: Placebo, treatment of symptomatic urinary tract infection only, short course therapy
Number of subjects: 46
Study 29052846 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet treatment (IT)
Number of subjects: 116
Study 29052846 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face group treatment (GT)
Number of subjects: 116
Study 29052846 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 116
Study 27184591 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine, 0.3-0.4 mg·kg(‐1) ·h(‐1) (Group R)
Number of subjects: 49
Study 27184591 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group C)
Number of subjects: 49
Study 27184591 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine (Group R)
Number of subjects: 49
Study 25264990 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost/Timolol Fixed Combination (LTFC)
Number of subjects: 90
Study 25264990 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost and Timolol Gel-forming Solution Unfixed Combination (LTuFC)
Number of subjects: 90
Study 23503739 — intervention group
Group type: EXPERIMENTAL
Intervention: activeTENS (transcutaneous electrical nerve stimulation during everyday activities)
Number of subjects: 29
Study 23503739 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (wearing the sock electrode with no stimulation)
Number of subjects: 29
Study 21319355 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 μg.kg⁻¹ remifentanil
Number of subjects: 40
Study 21319355 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo group)
Number of subjects: 40
Study 19145563 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Number of subjects: 4
Study 17046300 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg budesonide (B)
Number of subjects: 29
Study 17046300 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 or 10 mg montelukast (M)
Number of subjects: 29
Study 17046300 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg budesonide (B) + 5 or 10 mg montelukast (M)
Number of subjects: 29
Study 17046300 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg budesonide (B) + 9 microg formoterol (F)
Number of subjects: 29
Study 17046300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15124662 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency at 15 W
Number of subjects: 26
Study 15124662 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency at 30 W
Number of subjects: 26
Study 15124662 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency at 15 W
Number of subjects: 26
Study 15124662 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency at 30 W
Number of subjects: 26
Study 15124662 — intervention group
Group type: COMPARATOR
Intervention: No treatment (controls)
Number of subjects: 26
Study 11174813 — intervention group
Group type: EXPERIMENTAL
Intervention: Endograft aortic aneurysm (EAG) repair
Number of subjects: 368
Study 11174813 — intervention group
Group type: COMPARATOR
Intervention: Conventional open surgical (COS) repair
Number of subjects: 368
Study 10378674 — intervention group
Group type: EXPERIMENTAL
Intervention: Topitriol (calcitriol, 1,25-dihydroxyvitamin D3) cream (0.0025 or 0.005%; 25 and 50 microg/g concentration) administered topically twice a day. Doses evaluated: 500 and 1000 microg daily for 7 days prior to chemotherapy, and 2000 microg daily for 5 days prior and 5 days post‐chemotherapy.
Number of subjects: 14
Study 10378674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 7712314 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg sublingual GTN
Number of subjects: 6
Study 7712314 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/kg/h intravenous L‐arginine
Number of subjects: 6
Study 7712314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2654792 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (CPM) 2.5 mg/kg in 5 doses plus dexamethasone (DXM) 0.2 mg/kg in 2 doses
Number of subjects: 69
Study 2654792 — intervention group
Group type: COMPARATOR
Intervention: High-dose metoclopramide (HD-MCP) 10 mg/kg in 5 doses plus dexamethasone (DXM)
Number of subjects: 69
Study 55523 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU followed by bleomycin
Number of subjects: 35
Study 55523 — intervention group
Group type: COMPARATOR
Intervention: CCNU, bleomycin, methotrexate, and vinblastine
Number of subjects: 35
Study 31729622 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies synbiotic (probiotics and prebiotics)
Number of subjects: 26
Study 30548326 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive Behavior Prevention Program (ABPP) implemented for 12 weeks
Number of subjects: 90
Study 30548326 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 29275582 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole Capsules + Mosapride Citrate + Deanxit
Number of subjects: 125
Study 29275582 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole Capsules + Mosapride Citrate + Shuganjieyu capsule
Number of subjects: 125
Study 29275582 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole Capsules + Mosapride Citrate + Deanxit + Shuganjieyu capsule
Number of subjects: 125
Study 29275582 — intervention group
Group type: EXPERIMENTAL
Intervention: Deanxit
Number of subjects: 125
Study 29275582 — intervention group
Group type: COMPARATOR
Intervention: Control group (Lansoprazole Capsules + Mosapride Citrate)
Number of subjects: 125
Study 25899477 — intervention group
Group type: EXPERIMENTAL
Intervention: Xbox Kinect
Number of subjects: 30
Study 25899477 — intervention group
Group type: COMPARATOR
Intervention: Stationary cycle
Number of subjects: 30
Study 23653900 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX ARC (ARC)
Number of subjects: 72
Study 23653900 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem (RLXU)
Number of subjects: 72
Study 23653900 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem Elite (MCE)
Number of subjects: 72
Study 23653900 — intervention group
Group type: EXPERIMENTAL
Intervention: SeT (ST)
Number of subjects: 72
Study 23653900 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparations without restoration (WR)
Number of subjects: 72
Study 23653900 — intervention group
Group type: COMPARATOR
Intervention: Sound teeth (Control)
Number of subjects: 72
Study 20473134 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnestic multidomain MCI
Number of subjects: 447
Study 20473134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonamnestic multiple domain MCI
Number of subjects: 447
Study 20473134 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonamnestic single domain MCI
Number of subjects: 447
Study 20473134 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnestic single domain MCI
Number of subjects: 447
Study 20473134 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive deficits in at least 1 domain
Number of subjects: 447
Study 20473134 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple cognitive domain deficits
Number of subjects: 447
Study 20473134 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated memory deficit
Number of subjects: 447
Study 20473134 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated nonmemory deficit
Number of subjects: 447
Study 18374753 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vascular endothelial growth factor (VEGF) and L‐arginine (6 g per day for 3 months)
Number of subjects: 19
Study 16632816 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (n = 26)
Number of subjects: 76
Study 16632816 — intervention group
Group type: COMPARATOR
Intervention: Attention-control (n = 26)
Number of subjects: 76
Study 16632816 — intervention group
Group type: COMPARATOR
Intervention: Standard of care control (n = 24)
Number of subjects: 76
Study 12790506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide sedation (NO)
Number of subjects: 62
Study 12790506 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 62
Study 12790506 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied relaxation (AR)
Number of subjects: 62
Study 12790506 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 62
Study 10780630 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS
Number of subjects: 10
Study 10780630 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS
Number of subjects: 10
Study 2124732 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam enema (0.5 mg/kg bodyweight) in prone position
Number of subjects: 14
Study 2124732 — intervention group
Group type: COMPARATOR
Intervention: Diazepam enema (0.5 mg/kg bodyweight) in lateral position
Number of subjects: 14
Study 2124732 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam enema (0.5 mg/kg bodyweight)
Number of subjects: 14
Study 6101337 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 blocker (hydroxyzine HCl)
Number of subjects: 10
Study 6101337 — intervention group
Group type: EXPERIMENTAL
Intervention: H1 plus H2 blocker (hydroxyzine HCl + cimetidine)
Number of subjects: 10
Study 6101337 — intervention group
Group type: COMPARATOR
Intervention: H2 blocker (cimetidine)
Number of subjects: 10
Study 30592022 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 0
Study 28256066 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel (150 mg/m2 once per week for 3 of 4 weeks)
Number of subjects: 200
Study 28256066 — intervention group
Group type: COMPARATOR
Intervention: docetaxel (75 mg/m2 every 3 weeks)
Number of subjects: 200
Study 27430714 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (RT-CGM) alongside conventional intermittent home glucose monitoring (HGM)
Number of subjects: 324
Study 27430714 — intervention group
Group type: COMPARATOR
Intervention: HGM alone
Number of subjects: 324
Study 27430714 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-CGM
Number of subjects: 324
Study 25063045 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 1215
Study 25063045 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 1215
Study 25063045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1215
Study 25063045 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (both doses)
Number of subjects: 1215
Study 22209190 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 15 or 30 mg/day
Number of subjects: 66
Study 22209190 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium 900, 1200 or 1500 mg/day
Number of subjects: 66
Study 22209190 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 66
Study 22209190 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 66
Study 19160399 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent ESS and CR
Number of subjects: 13
Study 19160399 — intervention group
Group type: COMPARATOR
Intervention: CR only
Number of subjects: 13
Study 17173906 — intervention group
Group type: EXPERIMENTAL
Intervention: High-security straws (HSSs)
Number of subjects: 306
Study 17173906 — intervention group
Group type: COMPARATOR
Intervention: Conventional straws
Number of subjects: 306